The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Punit, so you base your comment on what is a 1 year target on short term fluctuation?
Oh dear....
Carry on punit you make laugh its better than watching the magic roundabout. Lol
How can you say £5 with the way it's going currently. It shows no hope.
" Imv you should review all of the reasons you invested against company performance every so often because things can change"
I am a specialist early stage Biotech Investor with 30 years experience in the sector, I continually review my investments and have entry and exit positions for them all
Tils, why not 10 years. Events. Imv you should review all of the reasons you invested against company performance every so often because things can change. Good luck.
I agree , £5 per share valuation is certainly possible for all assets including StemprintER , within a 5 - 10 year period ,which is the time people should expect to be invested to get that sort of return unless the Company or its assets are acquired
This one is my favourite investment! StemPrintER. will be a very nice earner (IMO). Foralumab is a game changer, massive upside here! I also think they're being very coy about the Covid treatment and expect more news on this very soon! I see absolutely no reason why we shouldn't see £5. IMO.... GLA
Mmm - if I was investing for 10 years I'd probably spread my risk a bit more than everything into one share. If I was doing a fire and forget then AZ.
I've made more then I lost in healthcare but I've had companies that fell over on the way - my winners take care of the losers - hence diversify my risk.
Just off to teach grandma how to suck eggs
Thanks a lot Alwaysone. With so many stings to their bow, even if one or two come good, the investment is safe. If more come good, my retirement would happen 5 years earlier ;). Also, there has been nothing much about covid after that presentation back in march.Are they holding back so that the focus is on Stem for now till they sell it off I wonder. Either way, no downside to it as covid is not really priced in atm. Another important aspect for me is, it looks like a small tight knit team who have already been together for 6-7 years which would help team spirit which is important when you are doing R&D day-in and day-out and may they all work together for the next decade and beyond. All these are what helped me make up my mind as I can not read charts and candles ;)
‘ stepped back out of the stock market for years’
Good luck TILS39. That’s a tidy investment and a good strategy. I did the same years ago and stepped back out of the for years until January this year. Price will probably go down before you buy your strategy will pay out for sure. Starting at 55p was a good call also.
Init to win it
I have been an avid reader of this share chat and this is my first post. Thanks to all the posters for the valuable info which helped me with my dd on TILS. I have started investing after the market crash so am a beginner learning the ropes about investing. I was looking to go as big as I could on one single stock and now am all in on TILS.My modest portfolio is 39k TILS shares bought between 55p and 110p and am locking them away for 10 years and no investment in any other shares(yet). If I am still alive and kicking in 2030, will come back in 2030 and update on this very board. Ofcourse if the company is not sold by then. My point is, if it is good enough for 2 years, why not 10? A team that can bring up so many block busters surely are going to bring many more in the coming years.Thanks safy, coffeecups, Invest and all the knowledgeable posters for helping rookies like myself with info.
Apologies not sure why I used the 10+ year example.
Feel free to read the above, most PI’s will be able to conclude whether the company timeframes match their ambitions.
Failing that I would stick to the broker targets of £5 for the year.
Rorkes - Same here. Good luck with that.
Tils’ plays are not a 10 year investment plan. Ofc anyone can keep shares as long as they wish. But the pipeline isn’t a 10 years wait. A bit of research on their website will tell you this.
Around 70% of potential new drugs pass Phase 1 and enter Phase 2, which continues to measure safety, while looking at how effective the treatment is, too. Phase 2 trials recruit up to several hundred patients with the condition to take part. This phase typically lasts several months to two years
Just 33% of drugs make it past Phase 2 and into Phase 3, which tests the potential treatment in the largest number of people. This phase measures both safety and effectiveness with many volunteers, sometimes thousands. Phase 3 trials last from one to three years.
After Phase 3, a pharmaceutical company may submit a New Drug Application (NDA) for the treatment to the Food and Drug Administration (FDA). The FDA then reviews results from all stages of the trial to determine whether it will approve the drug and allow the pharmaceutical company to begin marketing it to the public.
https://www.tizianalifesciences.com/our-drugs/
The link above shows the phases these drugs are at. Though for the latest update on miciclib refer to the RNS as the website needs updating.
Hope this helps.
I
Buffet also sold all his airlines stock earlier this year which have now combined rallied nearly 100% up. Think they called it Panic sold. According to his own rules a stock a market crash was also predicted around 6-8 weeks ago. Nobody is infallible.
The TILS broker target was 1 year and not 10+, most tils share holders are in it for that period or 24 months.
Safy - so before covid they were at a much lower valuation - I'm thinking most of the rise is due to covid test. My next move is to top up here rather than here cause the timelines are shorter and the risks lower - as you say none of their therapies are even preclinical yet.
There certainly are some people who post things on this board which clearly means they should not be invested in Biotech.
As Warren Buffett says:
“Invest Only in Companies You Understand”
Everyone who is invested here should research the Company, its pipeline and its future growth prospects based on that pipeline.
Biotech investing is really only for the specialist, well informed Investor willing to take a long term view, and by long term I do not mean 6 months or 1 year.
Safy , TILS SP is where it is due to past give aways, bucket loads of shares in CLNs, warrants, ATS etc.
Rorkes,
In their latest RNS the fundraiser for their cancer plays. Most drugs are not even at pre clinical stages. I think one of 5 drugs is. Top of my head.
I don’t dispute the potential at all in Avct, if they can nail the tests they’ll kill it. I’m invested for that. But I can’t get my head around how TILS have StemprintER, one drug at phase IIb, and the crown jewel entering phase II. The covid play, and I’m sure they have other bits and be stuck at 100p.
It takes an awful lot of time and costs into the millions to move from pre clinical to phase I and then to phase II. And it’s not a guaranteed success either. And yet still we are languishing behind.
Please don’t assume I’m against AVCT, I’m there and I can happily prove by showing my share certs. I guess I’m just saying the TILS is due a serious rerate if AVCT is correctly priced. Almost like a 100% rerate would just be scratching the surface.
Safy - I'm in both as well. Valuation for AVCT is shifting the existing market for Mab to affirmers in diagnostics and therapeutics. Huge but will require millions, time and a lot of misses on the way.
TILS has delivered more and has concrete assets. So less risky but much smaller potential.
Great to see two UK companies - being in both gives me some cover
For PI’s all these new RNS are old news. I blame JAdam for that (joke!!), he figured it all out and now everything seems to be a confirmation of what we knew. They can keep drip feeding the same information glossed up. We know the value. I think everyone does by now. I bet even the Tils leadership know this. There is real strong resistance here to move above 110-120. They have to bring something blockbuster to move beyond that. Or if there is an institutional seller, all shareholders must hope they quit selling or sell out quick. This seller has been here for at least 3 months. Look back at the comments on this board...
it’ll need an RNS with $$$ or expected earnings by X date to kick over £1.20p or some fruition on the Covid update (basically something new).
For miciclib if they are partnering with a big pharma for phase IIb, that news is needed with potential revenue targets if success is achieved. In a interview with the CEO (not chairman) he grinned when quizzed about this. That’s not to mean he has something in the pipeline but the grin alludes to knowing what we are all thinking. My gut feeling is something will come from miciclib partnership or StemprintER very soon.
The company also must realise that letting this go cold will reduce the SP short term especially when the chairman needs the SP above £3 for 3 months to really cash in.... unless people are cash rich and can afford to leave this in the bottom drawer and still have sufficient funds to continue trading people may look to companies like other covid or oil stocks by reducing their holdings here to get their Quick 10-20% margins there.
God willing the big gains will come. It’s just a question of people having the ability to ignore noise from other stocks, otherwise people may reduce holdings. The lure of a quick buck is often hard to resist. We already saw that on Friday where a regular poster wanted to cash out a few thousand. It’s perfectly ok to do that. But if everyone reduced their holdings.... people on twitter also post they have consolidated to go all in Tils. The problem right here, right now is.... We are regressing and that may cause twitchy fingers especially as other stocks are heading into the blue.
I’m in AVCT, Beyond the covid play...how that is higher than Tils is beyond me.
Just my thoughts.
Have not had desired effect nor has analyst ratings, the true value of this company is tenfold of avct, nyct, etc. With revenue due from stem 2021. The only thing I can think is that this is being held down for a takeover. American biotech are watching. The ever increasing free float will be hoovered up. The new shares issued have already been churned 3 fold. I cant see a overhang. Bwtfdik